Koken Licenses Alnylam's RNAi Patents for Research Uses | GenomeWeb

NEW YORK (GenomeWeb News) – Tokyo-based Koken has acquired the rights to use Alnylam Pharmaceuticals' RNAi-related patents under a non-exclusive, worldwide agreement, Alnylam said today.

Koken will use the patents from Alnylam's Kreutzer Limmer patent family, which covers aspects of the structure and functional properties of synthetic RNAi products, to manufacture and offer siRNA reagents to industry and academic researchers.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic analysis of pollutant-tolerant fish, and more.

Researchers have found a rare carbapenem resistance gene on a US pig farm, NBC News reports.

New York officials are considering the use of a familial DNA search to get a lead on a suspect in the strangulation death of a runner.

NIH Director Francis Collins has selected a retired Army major general and cardiologist for the CEO spot at the agency's embattled Clinical Center.